melanoma also redundantly known malignant type cancer develops pigmentproducing cells known melanomas typically occur skin may rarely occur mouth intestines eye uveal women commonly occur legs men commonly occur melanomas develop changes mole indicate melanoma include increase size irregular edges change color itchiness skin primary cause melanoma ultraviolet light uv exposure low levels skin pigment uv light may sun sources tanning many moles history affected family members poor immune function greater number rare genetic conditions xeroderma pigmentosum also increase diagnosis biopsy analysis skin lesion signs potentially using sunscreen avoiding uv light may prevent treatment typically removal melanoma potentially affected tissue border around melanoma slightly larger cancers nearby lymph nodes may tested spread people cured spread melanoma spread immunotherapy biologic therapy radiation therapy chemotherapy may improve treatment fiveyear survival rates united states among localized disease disease spread lymph nodes among distant likelihood melanoma reoccur spread depends thickness fast cells dividing whether overlying skin broken melanoma dangerous type skin globally newly occurred million people active disease resulted australia new zealand highest rates melanoma high rates also occur northern europe north america less common asia africa latin united states melanoma occurs times often men melanoma become common since areas mostly populated people european early signs melanoma changes shape color existing moles case nodular melanoma appearance new lump anywhere skin later stages mole may itch ulcerate bleed early signs melanoma summarized mnemonic classification apply nodular melanoma metastatic melanoma may cause nonspecific paraneoplastic symptoms including loss appetite nausea vomiting fatigue metastasis spread early melanoma possible relatively rare less fifth melanomas diagnosed early become metastatic brain metastases particularly common patients metastatic also spread liver bones abdomen distant lymph nodescitation needed melanomas usually caused dna damage resulting exposure uv light sun genetics also play melanoma also occur skin areas little sun exposure ie mouth soles feet palms hands genital people dysplastic nevus syndrome also known familial atypical multiple mole melanoma increased risk development moles indicates increased risk melanoma might arise weakened immune system makes cancer development easier due bodys weakened ability fight cancer uv radiation exposure tanning beds increases risk international agency research cancer finds tanning beds carcinogenic humans people begin using tanning devices age thirty years likely develop work airplanes also appear increased risk believed due greater exposure uvb light wavelengths nm sun absorbed skin cell dna results type direct dna damage called cyclobutane pyrimidine dimers thymine cytosine cytosinethymine dimers formed joining two adjacent pyrimidine bases within dna strand somewhat similarly uvb uva light longer wavelengths nm sun tanning beds also directly absorbed skin dna efficiency exposure radiation uva uvb one major contributors development occasional extreme sun exposure resulting sunburn causally related melanoma common back men legs women areas intermittent sun exposure risk appears strongly influenced socioeconomic conditions rather indoor versus outdoor occupations common professional administrative workers unskilled factors mutations total loss tumor suppressor genes use sunbeds deeply penetrating uva rays linked development skin cancers including possible significant elements determining risk include intensity duration sun exposure age sun exposure occurs degree skin pigmentation melanoma rates tend highest countries settled migrants northern europe large amount direct intense sunlight skin settlers adapted notably australia exposure childhood important risk factor exposure adulthood seen migration studies multiple severe sunburns increases likelihood future sunburns develop melanoma due cumulative sun tanning beds main sources uv radiation increase risk living close equator increases exposure uv number rare mutations often run families greatly increase melanoma several genes increase risks rare genes relatively high risk causing melanoma common genes gene called causes red hair relatively lower elevated risk genetic testing used search mutationscitation needed one class mutations affects gene alternative reading frame mutation gene leads destabilization transcription factor involved apoptosis human cancers another mutation gene results nonfunctional inhibitor cyclindependent kinase promotes cell division mutations cause skin condition xeroderma pigmentosum xp also increase melanoma susceptibility scattered throughout genome mutations reduce cells ability repair dna xp mutations highly penetrant chances carrier express phenotype highcitation needed familial melanoma genetically loci familial melanoma appear chromosome arms multiple genetic events related melanomas pathogenesis disease multiple tumor suppressor gene encodes lowmolecular weight protein inhibitor cyclindependent protein kinases cdks localised region human chromosome fammm typically characterized combined moles addition family history transmitted autosomal dominantly mostly associated people mutation associated fammm fold increased risk pancreatic mutations confer lower risk common population people mutations gene two four times likely develop melanoma two wildtype typical unaffected type copies mutations common redhaired people mutated copycitation needed mutation gene associated increased risks younger fair redhaired people persons multiple atypical nevi dysplastic nevi persons born giant congenital melanocytic nevi increased family history melanoma greatly increases persons risk mutations several genes found melanomaprone people history one melanoma increased risk developing second primary fair skin result less melanin skin means less protection uv radiation earliest stage melanoma starts melanocytes begin outofcontrol growth melanocytes found outer layer skin epidermis next layer dermis early stage disease called radial growth phase tumor less mm thick spreads level basal cancer cells yet reached blood vessels deeper skin unlikely earlystage melanoma spread parts body melanoma detected stage usually completely removed surgerycitation needed tumor cells start move different direction vertically epidermis papillary dermis cell behaviour changes next step evolution invasive radial growth phase individual cells start acquire invasive potential point melanoma capable spreadingcitation needed breslows depth lesion usually less mm clark level usually vertical growth phase vgp following invasive melanoma tumor becomes able grow surrounding tissue spread around body blood lymph vessels tumor thickness usually mm tumor involves deeper parts dermis host elicits immunological reaction tumor judged presence activity tumor infiltrating lymphocytes tils cells sometimes completely destroy primary tumor called regression latest stage development certain cases primary tumor completely destroyed metastatic tumor discovered human melanomas contain activating mutations affecting structure braf protein resulting constitutive signaling raf map kinase cause common cancers damage uva light mainly causes thymine uva also produces reactive oxygen species inflict dna damage primarily singlestrand breaks oxidized pyrimidines oxidized purine mutagenic dna change frequencies uvainduced thymine dimers respectively unrepaired cpd photoproducts lead mutations inaccurate translesion synthesis dna replication repair frequent mutations due inaccurate synthesis past cpds cytosine thymine ct cctt transition mutations commonly referred uv fingerprint mutations specific mutation caused uv frequently found sunexposed skin rarely found internal errors dna repair uv photoproducts inaccurate synthesis past photoproducts also lead deletions insertions chromosomal translocations entire genomes melanomas average mutated bases mostly ct transitions structural rearrangements found per melanoma genome much higher roughly mutations across generations parent among melanomas proteincoding genes missense nonsense splice site mutations transcriptomes melanomas also sequenced analyzed almost human proteincoding genes expressed melanoma genes also expressed normal cancer tissues genes showing specific expression pattern melanoma compared forms cancer examples melanoma specific genes tyrosinase mlana uv radiation causes damage dna cells typically thymine dimerization unrepaired create mutations cells genes strong mutagenic factor makes cutaneous melanoma tumor type highest number cell divides mutations propagated new generations cells mutations occur protooncogenes tumor suppressor genes rate mitosis mutationbearing cells become uncontrolled leading formation tumor data patients suggest aberrant levels activating transcription factor nucleus melanoma cells associated increased metastatic activity melanoma studies mice skin cancer tend confirm role activating transcription cancer cancer stem cells may also largescale studies cancer genome atlas characterized recurrent somatic alterations likely driving initiation development cutaneous melanoma cancer genome atlas study established four subtypes braf mutant ras mutant mutant triple frequent mutation occurs codon braf cases braf normally involved cell growth specific mutation renders protein constitutively active independent normal physiological regulation thus fostering tumor ras genes nras hras kras also recurrently mutated tcga cases mutations codons trigger oncogenic activity lossoffunction mutations often affect tumor suppressor genes oncogenic alterations include fusions involving various kinases alk ret braf ras mutations kinase fusions remarkably mutually exclusive occur different subsets patients assessment mutation status therefore improve patient stratification inform targeted therapy specific inhibitorscitation needed cases mutated versions braf nras undergo copynumber research done sarnas team proved heavily pigmented melanoma cells youngs modulus nonpigmented ones another experiment found elasticity melanoma cells important metastasis growth nonpigmented tumors bigger pigmented much easier spread shown pigmented nonpigmented cells melanoma tumors drugresistant looking visually inspecting area question common method suspecting moles irregular color shape typically treated candidates detect melanomas increase survival rates recommended learn recognize see abcde mnemonic regularly examine moles changes shape size color itching bleeding consult qualified physician candidate inperson inspection suspicious skin lesions accurate visual inspection images suspicious skin used trained specialists dermoscopy helpful identify malignant lesions use naked eye reflectance confocal microscopy may better sensitivity specificity dermoscopy diagnosing cutaneous melanoma studies needed confirm however many melanomas present lesions smaller mm diameter melanomas malignant first appear small dot physicians typically examine moles including less mm diameter seborrheic keratosis may meet abcd criteria lead false alarms doctors generally distinguish seborrheic keratosis melanoma upon examination dermatoscopycitation needed advocate replacing enlarging evolving moles change evolve concern alternatively practitioners prefer elevation elevation help identify melanoma lack elevation mean lesion melanoma melanomas us detected become elevated time elevation visible may progressed dangerous invasive stagecitation needed melanoma skin biopsy stain case may represent superficial spreading melanoma lymph node almost complete replacement metastatic melanoma brown pigment focal deposition melanin dermatoscope malignant melanoma right posterior thigh melanoma situ vertex scalp marked biopsy malignant melanoma situ evolving right clavicle marked biopsy malignant melanoma vertex scalp marked biopsy malignant melanoma right medial thigh marked biopsy malignant melanoma right posterior shoulder circled biopsy malignant melanoma left forearm marked biopsy malignant melanoma left forearm post excision pursestring closure melanoma situ right forehead marked biopsy melanoma situ dermatoscope image right forehead marked biopsy malignant melanoma situ evolving medial right temple adjacent sebaceous hyperplasia lateral malignant melanoma situ left anterior shoulder marked biopsy malignant melanoma situ right anterior shoulder marked biopsy malignant melanoma situ left upper inner arm malignant melanoma situ marked biopsy left forearm malignant melanoma situ right upper medial back marked biopsy malignant melanoma mid frontal scalp malignant melanoma left midback marked biopsy malignant melanoma left midback marked biopsy dermatoscope gross pathology melanoma metastasis pigmentforming vast majority cases giving dark appearance one method ugly duckling correlation common lesion characteristics made lesions deviate common characteristics labeled ugly duckling professional exam required little red riding hood suggests individuals fair skin lightcolored hair might difficulttodiagnose amelanotic melanomas extra care required examining individuals might multiple melanomas severely dysplastic nevi dermatoscope must used detect ugly ducklings many melanomas individuals resemble nonmelanomas considered wolves sheeps fairskinned individuals often lightly pigmented amelanotic melanomas present easytoobserve color changes variations borders often indistinct complicating visual identification without dermatoscope amelanotic melanomas melanomas arising fairskinned individuals difficult detect fail show many characteristics abcd rule break ugly duckling sign hard distinguish acne scarring insect bites dermatofibromas lentigines following visual examination dermatoscopic vivo diagnostic tools confocal microscope doctor may biopsy suspicious mole skin biopsy performed local anesthesia often required assist making confirming diagnosis defining severity elliptical excisional biopsies may remove tumor followed histological analysis breslow scoring incisional biopsies punch biopsies usually contraindicated suspected melanomas possibility sampling local implantation causing misestimation tumour however fears biopsies may increase risk metastatic disease seem total body photography involves photographic documentation much body surface possible often used followup highrisk patients technique reported enable early detection provides costeffective approach digital camera efficacy questioned due inability detect macroscopic diagnosis method used conjunction replacement dermoscopic imaging combination methods appearing give extremely high rates detection melanoma type neuroectodermal four main types histopathologic types melanoma situ invaded beyond basement membrane whereas invasive melanoma spread beyond histopathological types melanoma inherently invasive including nodular melanoma lentigo maligna melanoma situ counterpart lentigo maligna melanoma lentigo lentigo maligna sometimes classified early sometimes precursor superficial spreading melanomas acral lentiginous melanomas either situ acral lentiginous melanomas almost always context cancer staging available tnm metastatic melanomas detected xrays ct scans mris pet petcts ultrasound ldh testing photoacoustic however lack evidence accuracy staging people melanoma various imaging melanoma stages according ajcc stage require n lymph node class stage require metastasis status older systems include clark level breslows depth quantifying microscopic depth tumor invasion lactate dehydrogenase ldh tests often used screen metastases although many patients metastases even endstage normal ldh extraordinarily high ldh often indicates metastatic spread disease liver common patients diagnosed melanoma chest xrays ldh test cases ct mri andor pet scans although controversial sentinel lymph node biopsies examination lymph nodes also performed patients assess spread lymph nodes diagnosis melanoma supported presence protein marker monoclonal antibody reacts antigen present melanocytic tumors melanomas used anatomic pathology marker tumors antibody generated extract melanoma reacts positively melanocytic tumors tumors thus demonstrating specificity sensitivity antibody also reacts positively junctional nevus cells intradermal nevi fetal melanocytes normal adult melanocytes nonreactive almost nonmelanoma human malignancies exception rare tumors showing evidence melanogenesis eg pigmented schwannoma clear cell sarcoma tumors associated tuberous sclerosis complex angiomyolipoma lymphangiomyoma evidence support refute adult population screening malignant minimizing exposure sources ultraviolet radiation sun following sun protection measures wearing sun protective clothing longsleeved shirts long trousers broadbrimmed hats offer protection using artificial light tanning believed help prevent skin cancers actually lead increased incidence uv nail lamps used nail salons dry nail polish another common widespread source uv radiation could although risk developing skin cancer uv nail lamp use low still recommended wear fingerless gloves andor apply spf greater sunscreen hands using uv nail body uses uv light generate vitamin need balance getting enough sunlight maintain healthy vitamin levels reducing risk melanoma takes around halfhour sunlight body generate vitamin day amount time takes fairskinned people get sunburn exposure sunlight intermittent instead one sunscreen appears effective preventing past use sunscreens sun protection factor spf rating higher exposed areas recommended older sunscreens effectively blocked uva higher currently newer sunscreen ingredients avobenzone zinc oxide titanium dioxide effectively block uva uvb even lower spfs sunscreen also protects squamous cell carcinoma another skin concerns raised sunscreen might create false sense security sun review found tentative evidence statin fibrate medication may decrease risk review however support confirmation clinical diagnosis done skin biopsy usually followed wider excision scar tumor depending stage sentinel lymph node biopsy may performed controversy exists around trial evidence sentinel lymph node unclear evidence benefit treatment advanced malignant melanoma performed multidisciplinary approach excisional biopsies may remove tumor surgery often necessary reduce risk recurrence complete surgical excision adequate surgical margins assessment presence detectable metastatic disease along short longterm followup standard often done wide local excision wle cm margins melanomainsitu lentigo malignas treated narrower surgical margins usually cm many surgeons consider cm standard care standard excision cm margin might acceptable margin controlled surgery mohs surgery doublebladed technique margin control wide excision aims reduce rate tumor recurrence site original lesion common pattern treatment failure melanoma considerable research aimed elucidate appropriate margins excision general trend toward less aggressive treatment last metaanalysis randomized controlled trials found small difference survival rates favoring wide excision primary cutaneous melanomas results statistically mohs surgery reported cure rate low high ccpdma double scalpel peripheral margin controlled surgery equivalent mohs surgery effectiveness intraepithelial type melanoma melanomas spread usually lymph nodes area tumor spreading elsewhere attempts improve survival removing lymph nodes surgically lymphadenectomy associated many complications overall survival benefit recently technique sentinel lymph node biopsy developed reduce complications lymph node surgery allowing assessment involvement nodes biopsy sentinel lymph nodes widely used procedure treating cutaneous neither sentinel lymph node biopsy diagnostic tests performed evaluate early thin melanoma including melanoma situ melanoma melanoma people conditions unlikely cancer spread lymph nodes anywhere else survival rate considerations sentinel lymph node biopsy considered unnecessary health care furthermore baseline blood tests radiographic studies performed based identifying kind melanoma accurate tests detecting cancer tests high falsepositive potentially correct false positives gene expression profiling may used auxiliary testing ambiguous small sentinel lymph node biopsy often performed especially tumors mucosal tumors ocular melanoma tumors limbscitation needed process called lymphoscintigraphy performed radioactive tracer injected tumor site localize sentinel nodes precision provided using blue tracer dye surgery performed biopsy nodes routine hematoxylin eosin immunoperoxidase staining adequate rule node involvement polymerase chain reaction pcr tests nodes usually performed test entry clinical trials demonstrate many patients negative sentinel lymph node actually small number positive cells nodes alternatively fineneedle aspiration biopsy may performed often used test masses lymph node positive depending extent lymph node spread radical lymph node dissection often performed disease completely resected patient considered adjuvant therapy excisional skin biopsy management choice suspect lesion totally removed adequate minimal usually mm ellipse surrounding skin avoid disruption local lymphatic drainage preferred surgical margin initial biopsy narrow mm biopsy include epidermal dermal subcutaneous layers skin enables histopathologist determine thickness melanoma microscopic examination described breslows thickness measured millimeters however large lesions suspected lentigo maligna lesions surgically difficult areas face toes fingers eyelids small punch biopsy representative areas give adequate information disrupt final staging depth determination circumstances initial biopsy include final surgical margin cm cm cm misdiagnosis result excessive scarring morbidity procedure large initial excision disrupt local lymphatic drainage affect lymphangiogramdirected lymphnode dissection small punch biopsy used time logistical personal reasons patient refuses invasive excisional biopsy small punch biopsies minimally invasive heal quickly usually without noticeable scarring highrisk melanomas may require adjuvant treatment although attitudes vary different countries united states patients otherwise good health begin year highdose interferon treatment severe side effects may improve patients prognosis however british association dermatologists guidelines melanoma state interferon recommended standard adjuvant treatment metaanalysis suggested addition interferon alpha increased diseasefree averall survival people ajcc tnm stage iiiii cutaneous metaanalysis showed interferon could lengthen time melanoma comes back increased survival years unpleasant side effects also greatly decrease quality european union interferon usually used outside scope clinical chemotherapy drugs dacarbazine backbone metastatic melanoma treatment since fda approval however efficacy terms survival never proven people locally advanced cutaneous malignancies sarcoma isolated limb infusion ili found minimally invasive welltolerated procedure delivering regional melanoma cells mutations allow survive grow indefinitely smallmolecule targeted therapies work blocking genes involved pathways tumor proliferation main treatments braf ckit nras inhibitors work inhibit downstream pathways involved cell proliferation tumour development due specific gene people treated smallmolecule targeted inhibitors positive specific braf inhibitors vemurafenib dabrafenib mek inhibitor trametinib effective approved treatments braf positive melanoma tumors develop resistance therapy make therapy longer effective combining use braf mek inhibitors may create fast lasting melanoma therapy number treatments improve survival traditional biochemotherapy chemotherapy cytokines ifnα combined braf inhibitors improved survival people braf positive biochemotherapy alone improve overall survival higher toxicity combining multiple chemotherapy agents polychemotherapy improve survival targeted therapies result relatively short progressionfree survival pfs times therapy combination dabrafenib trametinib pfs pfs immunotherapy aimed stimulating persons immune system tumor enhancing bodys ability recognize kill cancer current approach treating melanoma immunotherapy includes three broad categories treatments including cytokines immune check point inhibitors adoptive cell treatment options often used people metastatic melanoma significantly improves overall however treatments often costly example one immune check point inhibitor treatment pembrolizumab costs single dose administered every cytokine therapies used melanoma include ifna proleukin first new therapy approved eu us treatment metastatic melanoma may offer possibility complete longlasting remission disease small percentage people intralesional intransit metastases high complete response rate ranging similarly ifna shown modest survival benefits high toxicity limiting use standalone immune check point inhibitors include monoclonal antibodies ipilimumab tremelimumab tolllike receptor tlr agonists agonists pembrolizumab pidilizumab nivolumab evidence suggests antibodies effective antibodies less systemic fiveyear progressionfree survival immunotherapy pembrolizumab therapeutic approach includes combination different therapies improves overall survival progressionfree survival compared treatment separate immunotherapy drugs ongoing research looking treatment adoptive cell adoptive cell transfer refers application prestimulated modified cells dendritic cells presently used minimize complications graftversushost combination nivolumabrelatlimab opdualag approved medical use united states march standard excision still done surgeons unfortunately recurrence rate exceedingly high due illdefined visible surgical margin facial location lesions often forcing surgeon use narrow surgical margin narrow surgical margin used combined limitation standard breadloafing technique fixed tissue histology result high false negative error rate frequent recurrences margin control peripheral margins necessary eliminate false negative errors bread loafing used distances sections approach mm assure method approaches complete margin control metaanalysis literature found randomized controlled trials surgical interventions treat lentigo maligna melanoma insitu even though surgery widely used mohs surgery done cure rate reported low high another double scalpel peripheral margin controlled excision method approximates mohs method margin control requires pathologist intimately familiar complexity managing vertical margin thin peripheral sections staining melanocytic nevi melanomainsitu lentigo maligna resolved experimental treatment imiquimod aldara topical cream immune enhancing agent dermasurgeons combining methods surgically excising cancer treating area aldara cream postoperatively three months studies suggested adjuvant use topical tazarotene current evidence insufficient recommend suggests increases topical inflammation leading lower patient radiation therapy often used surgical resection patients locally regionally advanced melanoma patients unresectable distant metastases kilovoltage xray beams often used treatments property maximum radiation dose occurring close skin may reduce rate local recurrence prolong radioimmunotherapy metastatic melanoma currently investigation radiotherapy role palliation metastatic factors affect prognosis include certain types melanoma worse prognoses explained thickness less invasive melanomas even lymph node metastases carry better prognosis deep melanomas without regional metastasis time staging local recurrences tend behave similarly primary unless site wide local excision opposed staged excision punchshave excision since recurrences tend indicate lymphatic invasion melanomas spread lymph nodes one important factors number nodes malignancy extent malignancy within node also important micrometastases malignancy microscopic favorable prognosis macrometastases cases micrometastases may detected special staining malignancy detectable rarely employed test known polymerase chain reaction pcr prognosis better macrometastases malignancy clinically apparent cases cancer completely replaces node far worse prognosis nodes matted extracapsular extension prognosis worse still addition variables expression levels copy number variations number relevant genes may used support assessment malignant melanoma stage iv melanoma metastasized deadly skin malignancy fiveyear survival distant metastasis cancer generally considered incurable fiveyear survival rate less median survival months treatment palliative focusing life extension quality life cases patients may live many months even years metastatic melanoma depending aggressiveness treatment metastases skin lungs better prognosis metastases brain bone liver associated worse prognosis survival better metastasis location primary tumor enough definitive evidence adequately stage thus give prognosis ocular melanoma melanoma soft parts mucosal melanoma eg rectal melanoma although tend metastasize easily even though regression may increase survival melanoma regressed impossible know original size thus original tumor often worse pathology report might indicate genes prognostic melanoma unfavorable genes high expression correlated poor survival favorable genes high expression associated longer survival times examples unfavorable genes timeless example favorable gene increased neutrophiltolymphocyte ratio associated worse globally melanoma occurred people resulted australia new zealand highest rates melanoma become common last years areas mostly rate melanoma increased recent years clear extent changes behavior environment early detection australia high increasing rate melanoma deaths melanoma occurred per population australia melanoma third common cancer either sex indeed incidence higher lung cancer although latter accounts deaths estimated australians diagnosed melanoma given australias modest population better expressed new cases per population per year new cancer cases melanoma incidence australia matter significance following reasons united states people die melanoma affected per resulted death per american cancer societys estimates melanoma incidence united states melanoma times common whites african americans overall lifetime risk getting melanoma whites african americans hispanics risk melanoma increases people age average age people disease diagnosed although melanoma new disease evidence occurrence antiquity rather scarce however one example lies examination nine peruvian mummies radiocarbon dated approximately years old showed apparent signs melanoma melanotic masses skin diffuse metastases john hunter reported first operate metastatic melanoma although knowing precisely described cancerous fungous excrescence excised tumor preserved hunterian museum royal college surgeons england microscopic examination specimen revealed example metastatic french physician rené laennec first describe melanoma disease entity report initially presented lecture faculté de médecine de paris published bulletin first englishlanguage report melanoma presented english general practitioner stourbridge william norris later work remarked familial predisposition development melanoma eight cases melanosis pathological therapeutical remarks disease norris also pioneer suggesting link nevi melanoma possibility relationship melanoma environmental exposures observing patients pale also described melanomas could amelanotic later showed metastatic nature melanoma observing disseminate visceral organs first formal acknowledgment advanced melanoma untreatable came samuel cooper stated chance cure depends upon early removal disease ie early excision malignant mole one half centuries later situation remains largely unchanged word melanoma came english uses combining forms derived ancient greek roots melano denoting melanin oma denoting tissue mass especially neoplasm turn greek μέλας melas ωμα oma process word melanoma long history used broader sense refer melanocytic tumor typically always today narrower sense referring malignant types become dominant benign tumors usually called melanomas anymore word melanoma usually taken mean malignant melanoma unless otherwise specified terms benign melanocytic tumor unequivocally label benign types modern histopathologic tumor classifications used medicine use word benign tumors pharmacotherapy research unresectable metastatic malignant melanoma clinical research adoptive cell therapy gene therapy two kinds experimental treatments developed national cancer institute nci used metastatic melanoma tentative first treatment involves adoptive cell therapy act using tils immune cells tumorinfiltrating lymphocytes isolated persons melanoma cells grown large numbers laboratory returned patient treatment temporarily reduces normal cells patients body til therapy following lymphodepletion result durable complete response variety second treatment adoptive transfer genetically altered autologous lymphocytes depends delivering genes encode called cell receptors tcrs patients manipulation lymphocytes recognize bind certain molecules found surface melanoma cells kill cancer vaccine showed modest benefit latestage testing melanomas contain mutation braf gene early clinical trials suggested braf inhibitors including plexxicons vemurafenib could lead substantial tumor regression majority patients tumor contain braf june large clinical trial confirmed positive findings earlier august vemurafenib received fda approval treatment latestage melanoma may us fda approved dabrafenib single agent treatment patients braf mutationpositive advanced researchers believe combination therapies simultaneously block multiple pathways may improve efficacy making difficult tumor cells mutate destroyed october study reported combining dabrafenib mek inhibitor trametinib led even better outcomes compared dabrafenib alone progressionfree survival increased median progressionfree survival increased months versus months side effects however increased combined january fda approved combination dabrafenib trametinib treatment people braf metastatic june fda approved combination braf inhibitor encorafenib mek inhibitor binimetinib treatment unresectable metastatic melanoma braf eventual resistance braf mek inhibitors may due cell surface protein known american society clinical oncology conference june bristolmyers squibb pharmaceutical company reported clinical findings drug ipilimumab study found increase median survival months patients advanced melanomas treated monoclonal ipilimumab versus experimental vaccine also found oneyear survival rate control group using vaccine vaccine ipilimumab group group treated ipilimumab however raised concerns study use unconventional control arm rather comparing drug placebo standard criticism although ipilimumab performed better vaccine vaccine tested may causing toxicity making drug appear better comparison ipilimumab approved fda march treat patients latestage melanoma spread removed june clinical trial ipilimumab plus dacarbazine combined immune system booster standard chemotherapy drug targets cell division showed increase median survival late stage patients months instead months normally seen researchers also hopeful improving five year survival rate though serious adverse sideeffects seen patients course treatment costs drugs brandname advances high resolution ultrasound scanning enabled surveillance metastatic burden sentinel lymph screening surveillance ultrasound melanoma trial sunmel evaluating ultrasound alternative invasive surgical countries oncolytic virotherapy methods studied used treat melanoma oncolytic virotherapy promising branch virotherapy oncolytic viruses used treat diseases viruses increase metabolism reduce antitumor immunity disorganize talimogene laherparepvec tvec herpes simplex virus type oncolytic immunotherapy shown useful metastatic melanoma increased survival httpsenwikipediaorgwikimelanoma